Novel approach to the eradication of Pseudomonas aeruginosa in an infant with CF after outpatient treatment failure

Pediatr Pulmonol. 2008 May;43(5):511-3. doi: 10.1002/ppul.20791.


Intravenous continuous infusion of betalactam (CIBL) antibiotic and high dose extended interval (HDEI) aminoglycoside therapy theoretically maximize bacterial killing in treatment of Pseudomonas aeruginosa (PsA) in pulmonary exacerbations of cystic fibrosis (CF). We present the case of a 3-month-old female infant with CF who failed outpatient eradication of PsA with subsequent eradication using intravenous CIBL antibiotic and HDEI aminoglycoside therapy. This antibiotic combination should be considered in order to optimize pharmacodynamics for PsA eradication in CF patients before development of chronic colonization.

Publication types

  • Case Reports

MeSH terms

  • Aminoglycosides / administration & dosage
  • Aminoglycosides / therapeutic use*
  • Anti-Bacterial Agents / administration & dosage
  • Anti-Bacterial Agents / therapeutic use*
  • Area Under Curve
  • Cystic Fibrosis / microbiology*
  • Dose-Response Relationship, Drug
  • Drug Therapy, Combination
  • Female
  • Humans
  • Infant
  • Infusions, Intravenous
  • Inpatients
  • Outpatients
  • Pseudomonas Infections / drug therapy*
  • Pseudomonas aeruginosa / drug effects*
  • Pseudomonas aeruginosa / isolation & purification
  • Treatment Failure
  • Treatment Outcome
  • beta-Lactams / administration & dosage
  • beta-Lactams / therapeutic use*


  • Aminoglycosides
  • Anti-Bacterial Agents
  • beta-Lactams